BGLC
BioNexus Gene Lab Corp.
There isn't enough reported data to score BGLC yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
BGLC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
BGLC's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BGLC PE Valuation
BGLC has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BGLC Forward outlook
There aren't enough analyst estimates for BGLC to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BGLC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$0.07 | -105% |
| Q2 2022 | -$0.02 | -101% |
| Q1 2022 | $0.07 | -95% |
| Q4 2021 | $0.06 | -96% |
| Q3 2021 | $1.44 | +586% |
| Q2 2021 | $1.44 | +586% |
| Q1 2021 | $1.44 | +1340% |
| Q4 2020 | $1.44 | +$1.44 |
NVO has the stronger earnings trend. Trailing diluted EPS is down 1,943% for BGLC versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
BGLC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $76.2K | -97% |
| Q1 2026 | $22.8K | -99% |
| Q4 2025 | $483.8K | -81% |
| Q3 2025 | $2.5M | -3.3% |
| Q2 2025 | $2.3M | +14% |
| Q1 2025 | $2.1M | -10% |
| Q4 2024 | $2.5M | +11% |
| Q3 2024 | $2.6M | +3% |
BGLC's revenue has slid since its 2020 peak: $76,156 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -371% | -344 points |
| Q1 2026 | -2366% | -2337 points |
| Q4 2025 | -214% | -197 points |
| Q3 2025 | -28% | +23 points |
| Q2 2025 | -27% | -40 points |
| Q1 2025 | -29% | -26 points |
| Q4 2024 | -16% | -28 points |
| Q3 2024 | -51% | +48 points |
BGLC's operating margin was −371% last quarter, down 344 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over BGLC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BGLC on profitability, with a higher operating margin.
BGLC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$422.7K | +$336.6K |
| Q1 2026 | -$148K | +$685.1K |
| Q4 2025 | $960.1K | +$1M |
| Q2 2025 | -$759.4K | -$88.8K |
| Q1 2025 | -$833.1K | -$798.7K |
| Q4 2024 | -$73.8K | +$39.7K |
| Q2 2024 | -$670.5K | -$634.1K |
| Q1 2024 | -$34.4K | +$84K |
BGLC has burned cash in most quarters: −$853,600 over the past year, against −$2M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over BGLC on cash generation, producing positive trailing cash flow while its opponent burns cash.
BGLC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +35% | +621K shares |
| 3 years | +37% | +647K shares |
| 5 years | +69% | +990K shares |
| Available history | +294% | +1.8M shares |
BGLC has 2M diluted shares, up 35% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over BGLC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BGLC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -3.9x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -2.2x | Net Cash |
| Q4 2021 | -1.9x | Net Cash |
| Q3 2021 | -0.7x | Net Cash |
| Q2 2021 | -0.8x | Net Cash |
| Q1 2021 | -1.4x | Net Cash |
| Q4 2020 | -2.0x | Net Cash |
BGLC has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
BGLC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 4.3 | Oversold |
BGLC's weekly RSI is 30 (oversold) and its Stochastic is 4 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BGLC PE vs Healthcare Sector
| Metric | BGLC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BGLC has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BGLC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.12 | 19% below |
| 20 week MA | $1.42 | 36% below |
| 50 week MA | $2.19 | 58% below |
| 100 week MA | $3.15 | 71% below |
| 200 week MA | $12.5 | 93% below |
BGLC is in a downtrend: it's below all five of its weekly moving averages, and 93% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over BGLC on trend strength, trading above more of its moving averages.
BGLC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $264.0 | $228.0 | -14% |
| 2022 | $228.0 | $114.0 | -50% |
| 2023 | $114.0 | $5.30 | -95% |
| 2024 | $5.30 | $2.67 | -50% |
| 2025 | $2.67 | $4.14 | +55% |
| 2026 YTD | $4.14 | $0.91 | -78% |
BGLC has finished lower in four of the last five years. It's down 78% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over BGLC on returns for 2026, with the stronger performance.